Anthera Pharmaceuticals (NASDAQ:ANTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Monday. The brokerage currently has a $1.75 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 20.69% from the stock’s previous close.
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
Separately, ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.32. During the same period in the prior year, the business posted ($4.85) EPS. equities analysts anticipate that Anthera Pharmaceuticals will post -3.02 EPS for the current year.
An institutional investor recently raised its position in Anthera Pharmaceuticals stock. Wedbush Securities Inc. increased its stake in shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 75.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,764 shares of the biopharmaceutical company’s stock after buying an additional 31,800 shares during the quarter. Wedbush Securities Inc. owned about 0.68% of Anthera Pharmaceuticals worth $106,000 at the end of the most recent reporting period. 16.10% of the stock is currently owned by hedge funds and other institutional investors.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.